Abstract:Abstract The human MHC class I -related chain gene A (MICA), a highly polymorphic MHC-encoded cell-surface glycoprotein, is a stress-induced and transformation related molecule absent from most normal tissues. Expression of MICA has been reported on a variety of mostly epithelial tumors. MICA can activate Natural Killer (NK) cells via interacting with the immunoreceptor NKG2D. Soluble MICA (sMICA), when shedded from tumor by the action of matrix-metalloproteinases (MMPs), can be detected at high levels in the sera of cancer patients. High levels of sMICA can down-regulate NKG2D expression and lead to functional impairment of NK cells thus providing for a mechanism of tumor escape. Gene array expression profiling of bone marrow biopsies revealed high levels of MMP2 and MMP9 in the bone marrow microenvironment, but not in the purified myeloma cells of the same patients. Since we are developing allogeneic NK cell therapy as a novel treatment for high-risk myeloma we decided to study whether the high activity of MMP2 and MMP9 resulted in 1) elevated sMICA levels in myeloma, and 2) affected NKG2D expression by NK cells. We found by ELISA assays that 28% (13/46) of patients with MM at diagnosis contained elevated serum levels of sMICA (median: 265.2 pg/ml; range: 125.9 – 806.5 pg/ml). sMICA levels were low in 16 control healthy donors tested (median: 0.8 pg/ml; range: 0 – 91 pg/ml). Next, we correlated sMICA levels with indicators of tumor burden and prognosticators of outcome in MM. We observed that sMICA levels in the serum of MM patients was not associated with Ras associated oncogene (RAN) expression, presence of abnormal cytogenetics, elevated CRP, elevated b2-microglobulin or elevated serum M-protein levels. There was also no correlation between MICA gene expression in purified MM cells and increased sMICA levels in the serum. We therefore examined several myeloma cell lines and found that high MICA gene expression does not always correlate with MICA expression at the cell surface as detected by flow cytometry. We hypothesize that the lack of correlation between MICA RNA expression and sMICA may be due to variation in translation of the MICA mRNA or failure to transport the MICA protein to the cell surface. Further, we tested the expression of NKG2D on CD3−/CD56+ cells of 5 MM patients with elevated sMICA serum levels and detected no down-regulation of NKG2D on NK cells compared to controls comprising MM patients with normal sMICA levels (n=3) or normal donors (n=5). Recent studies have suggested that tumor-membrane bound MICA may also play a role in the down-regulation of NKG2D on NK cells. We next incubated normal donor NK cells with a) the high membrane bound MICA expressing MM cell line U266 or b) serum from MM patients containing high MICA levels neither of which resulted in down-regulation of NKG2D. We conclude that despite the high expression of MMP2 and MMP9 both soluble or membrane bound MICA do not down-regulate NKG2D on NK cells and hence do not adversely affect NK cell function in MM. One explanation may be that the sMICA levels we found in myeloma patients were in the order of pg/ml, whilst the levels reported in epithelial tumors are 2–3 logs higher.

Relationship Between NF-κB, MMP-9, and MICA Expression in Pituitary Adenomas Reveals a New Mechanism of Pituitary Adenomas Immune Escape

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

The clinical and biological significance of MICA in clear cell renal cell carcinoma patients

The Relationship Between MRI Invasive Features and Expression of EMMPRIN, Galectin-3, and Microvessel Density in Pituitary Adenoma

Matrix Metalloproteinase 9 for Evaluating Invasiveness and Recurrence in Pituitary Adenoma Patients: A Meta-analysis

Matrix Metallopeptidase 2 (MMP2) Mediates MHC Class I Polypeptide-Related Sequence A (MICA) Shedding in Renal Cell Carcinoma

Diagnosis of invasive non-functional pituitary adenomas using exosomal biomarkers

Immune evasion by TGFβ-induced miR-183 repression of MICA/B expression in human lung tumor cells

MICA+ Tumor Cell Upregulated Macrophage-Secreted MMP9 via PROS1-AXL Axis to Induce Tumor Immune Escape in Advanced Hepatocellular Carcinoma (HCC)

Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas Were Identified by Using Analysis of Micrornas Expression Profile

The relationship between expression of CD147, Galectin-3 and MVD and invasiveness of pituitary adenomas

Soluble And Membrane Bound Mica In Myeloma Do Not Adversely Effect Regulation Of Natural Killer Cell Function Via Nkg2d.

Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis

Magnetic Resonance Imaging and Biological Markers in Pituitary Adenomas with Invasion of the Cavernous Sinus Space

Alterations in CD8+ Tregs, CD56+ Natural Killer Cells and IL-10 Are Associated with Invasiveness of Nonfunctioning Pituitary Adenomas (Nfpas)

MEG3/MIR-376B-3P/HMGA2 axis is involved in pituitary tumor invasiveness

The miR-19a/Cylindromatosis Axis Regulates Pituitary Adenoma Bone Invasion by Promoting Osteoclast Differentiation

Novel Role of Immune-Related Non-Coding RNAs As Potential Biomarkers Regulating Tumour Immunoresponse Via MICA/NKG2D Pathway

Expression of Pituitary Tumor Transforming Gene, Basic Fibroblast Growth Factor and Proliferating Cell Nuclear Antigen in Human Pituitary Adenomas: Correlation with Invasiveness

Micrornas-Based Network: A Novel Therapeutic Agent in Pituitary Adenoma

MIF promotes perineural invasion through EMT in salivary adenoid cystic carcinoma